STORY -- A Pivotal Autism Clinical Trial Utilizing Illumina Next Generation Sequencing

While children can exhibit symptoms of autism spectrum disorders (ASDs) before 18 months, the current average age of diagnosis is 4.5 years – well past the age where behavioral therapies can begin.

SynapDx is developing a test to shorten the time from suspicion of autism to diagnosis. They chose Illumina next-generation sequencing technology as the platform for designing performance characteristics and be the basis for their roll out as a diagnostic test. Their clinical trial, a 600-patient study called STORY, is currently in progress.

See the video at:

Back to all News